Rwandan-Owned Akagera Medicines Wins $7.8 Million Gates Grant for TB Vaccine

KIGALI, RWANDA — The Akagera Medicines TB vaccine programme has received an additional $7.8 million (about Rwf11.5 billion) from the Gates Foundation to move its tuberculosis vaccine candidate towards a first human trial, The New Times reported on 19 November.
Akagera Medicines, a biotechnology company majority-owned by Rwandans, said the new funding brings the foundation’s total commitment to the vaccine programme to $9.79 million (about Rwf14.4 billion).
“With manufacturing and IND-enabling toxicology now funded, we have a clear path to our first-in-human study,” the company said, according to the report.
How the Akagera Medicines TB vaccine works
The vaccine is an mRNA candidate delivered by lipid nanoparticles to dendritic cells, immune cells that help the body recognise and respond to infections, The New Times reported. Research under the first Gates grant, awarded in August 2023, used mRNA encoding nine TB antigens.
“Targeting mRNA delivery to dendritic cells lets us focus on the immune response where it matters most for TB,” the company said.
The new funds will pay for manufacturing vaccine for clinical use, toxicology and safety studies, and the regulatory documents needed to apply to begin human trials, according to the report.
As general background, toxicology studies test a vaccine candidate’s safety in laboratory and animal studies before it can be given to people. An Investigational New Drug (IND) application is the formal request to regulators to begin human trials, and must include data on manufacturing, safety and the trial plan.
If the Akagera Medicines TB vaccine reaches human trials, it would first be tested in small groups of volunteers for safety, before larger trials to assess whether it prevents infection or disease.
The company is based in Waltham, Massachusetts. Daryl Drummond is co-founder and Chief Scientific Officer, and Michael Fairbanks is co-founder and Executive Chairman. Akagera also has a long-acting TB treatment candidate, AKG-100, the report said.
The company described its goal as “a vaccine designed from the start for the people and places that need it most.”
The global TB burden
Citing WHO figures, The New Times said about 10.6 million people fell ill with TB in 2025 and about 1.13 million died.
As general background, the only licensed TB vaccine, BCG, was developed more than a century ago. It protects young children against severe forms of TB but offers limited and variable protection against lung TB in adolescents and adults, who drive most transmission. A more effective vaccine is considered essential to ending the epidemic.
Several countries in Africa, including Nigeria and South Africa, are among those with the highest TB burdens in the world, according to WHO. Many people with TB are never diagnosed or treated, which allows the disease to continue spreading in households and communities.
TB is curable with a course of antibiotics lasting several months, but drug-resistant forms require longer, more complex treatment.
Prevention through an effective vaccine would reduce the cost and burden of treatment for patients and health systems alike.
Several TB vaccine candidates are in clinical trials worldwide, using different technologies. mRNA vaccines, which became widely known during the COVID-19 pandemic, can be designed and adapted relatively quickly, but TB has proved a difficult target because the bacterium evades the immune system in complex ways.
African ownership in vaccine research
The Akagera Medicines TB vaccine is notable for its Rwandan ownership. As general background, Africa carries a large share of the global TB burden but has historically had little ownership of the research, manufacturing and intellectual property behind new medicines and vaccines.
Rwanda has positioned itself as a hub for biotechnology and vaccine manufacturing, including through a BioNTech mRNA facility in Kigali. Locally owned companies developing products for African priorities could help reduce dependence on imports and ensure new tools are designed for African settings.
The Akagera Medicines TB vaccine work also reflects how philanthropic funding can support early-stage research in areas that commercial investors may consider too risky or less profitable.
TB remains a leading infectious killer in Africa and is closely linked to HIV, malnutrition and diabetes. People with diabetes have a higher risk of developing active TB, and TB can make blood sugar harder to control. HealthCoach Africa’s infections hub explains how TB spreads and how it is treated.
The company has not announced a date for its first human trial, which will depend on completing safety studies and obtaining regulatory approval.
Why it matters: TB kills more than a million people a year, and a Rwandan-owned mRNA vaccine could give Africa a stake in new tools to stop it.
Source: The New Times via allAfrica (Alice Umutesi), November 2026.



